Pilot XFBD in COVID-19

A Randomized, Double-Blind, Placebo-Control Pilot Trial of Xuanfei Baidu Granules (XFBD), a Traditional Chinese Medicine (TCM), in Persons with COVID-19:
FDA IND-150945, IRB HS-20-00632

The purpose of this study is to document the safety of taking traditional Chinese medicine (TCM) in patients with COVID-19 and to gain information to determine whether a study with TCM can be conducted. The study will test a traditional Chinese medicine that has been made into a granule formulation called Xuanfei Baidu Granules.

For more information contact: xfbd-info-l@mymaillists.usc.edu or call (818) 309 – 5542